[Shock-treatment in gastro-intestinal-bleeding with 3,5% isocyanate crosslinked polypeptide solution]

Area of Science:

• Biomedical Engineering
• Pharmacology
• Critical Care Medicine

Context:

• Gastro-intestinal bleeding is a common cause of hypovolemic shock.
• Effective volume replacement is crucial for managing shock and preventing complications.
• Haemaccel, a polypeptide solution, is used for volume expansion.

Purpose:

• To evaluate the efficacy and safety of Haemaccel (3.5% isocyanate crosslinked polypeptide solution) in patients with gastro-intestinal bleeding.
• To assess Haemaccel's ability to increase intravascular volume for shock treatment and prophylaxis.
• To monitor for any adverse events associated with Haemaccel administration.

Summary:

• A prospective study administered 500 ml of Haemaccel (3.5% isocyanate crosslinked polypeptide solution) to patients experiencing gastro-intestinal bleeding.
• The infusions successfully increased intravascular volume, meeting therapeutic goals for shock management.
• No adverse effects, including anaphylaxis, anaphylactoid reactions, coagulopathy, or oliguria, were observed during the study.

Impact:

• Haemaccel demonstrates a favorable safety profile and efficacy in managing hypovolemic shock secondary to gastro-intestinal bleeding.
• The findings support the use of Haemaccel as a reliable option for volume resuscitation in this patient population.
• This study contributes to the understanding of Haemaccel's clinical utility in critical care settings.